Abstract
CAR-T cell therapy has achieved remarkable success and effectiveness against hematological malignancy. However, transitions of CAR-T for solid tumor are restricted abruptly due to the tumor micro-environment. Recent studies revealed that various immune cells expressed in TME prevented T cell activation, greatly reducing the efficacy of CAR-T. At present, many clinical studies and trials have been conducted on gliomas, especially glioblastoma, demonstrating that the advantages and disadvantages of applying CAR-T in clinical practice are worth exploring. In this paper, the targets and positive effects of CAR-T for glioblastoma are discussed, as well as the negative effects of T regulatory cells, myeloid-derived suppressor cells, and tumor associated macrophages in tumor microenvironment. Simultaneously, this review also proposes a few suggestions for optimizing the CAR-T therapy for glioblastoma.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
